Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Vaccine|July 30, 2023
Thrombosis with thrombocytopenia syndrome: A database review of clinical trial and post-marketing experience with Ad26.COV2.SFrank Struyf, Karin Hardt, Rian Van Rampelbergh, et al.
Communications Medicine|May 10, 2025
Comparison of vaccine-induced immune thrombocytopenia and thrombosis cases following two adenovirus-vectored COVID-19 vaccinesRian Van Rampelbergh, Sue Pavord, Luis Anaya-Velarde, et al.
The Lancet. Infectious Diseases|September 16, 2022
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trialKarin Hardt, An Vandebosch, Jerald Sadoff, et al.
Familial Cancer|March 16, 2011
Missense variants in hMLH1 identified in patients from the German HNPCC consortium and functional studiesKarin Hardt, Sven Boris Heick, Beate Betz, et al.
The Lancet. Oncology|November 15, 2011
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialCosette M Wheeler, Xavier Castellsagué, Suzanne M Garland, et al.
Clinical and Vaccine Immunology : CVI|February 6, 2015
Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trialDan Apter, Cosette M Wheeler, Jorma Paavonen, et al.
The New England Journal of Medicine|April 21, 2021
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19Jerald Sadoff, Glenda Gray, An Vandebosch, et al.
The New England Journal of Medicine|February 9, 2022
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.SJerald Sadoff, Glenda Gray, An Vandebosch, et al.
Lancet (London, England)|September 6, 2014
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE studyS Rachel Skinner, Anne Szarewski, Barbara Romanowski, et al.
The Lancet. Infectious Diseases|July 5, 2016
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE studyCosette M Wheeler, S Rachel Skinner, M Rowena Del Rosario-Raymundo, et al.
Pageof 4